8-K current report · filed Oct 2, 2026

Cullinan Therapeutics, Inc. (CGEM) 8-K Current Report: October 2, 2026

Item 7.01Item 8.01Item EX-99.1CGEM overview

Short answer

Cullinan Therapeutics, Inc. (CGEM) filed an 8-K current report with the SEC on October 2, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). NDA submission initiated for zipalertinib plus platinum chemotherapy in previously untreated EGFR exon 20 insertion NSCLC.

Cullinan Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • NDA submission initiated for zipalertinib plus platinum chemotherapy in previously untreated EGFR exon 20 insertion NSCLC
  • FDA Real-Time Oncology Review designation could accelerate regulatory review and potential approval timing
  • Strategy expands zipalertinib toward first-line treatment, broadening its addressable NSCLC opportunity

Item 8.01 · Other Events

  • FDA NDA submission initiated for first-line zipalertinib plus chemotherapy in EGFR ex20ins NSCLC under RTOR
  • Phase 3 REZILIENT3 met its primary endpoint, showing statistically significant median progression-free survival improvement
  • Complete NDA submission expected by year-end 2026, potentially accelerating FDA review
  • Separate monotherapy NDA remains under review, with February 27, 2027 PDUFA target date
  • Taiho milestones: $30.0 million upon approval after prior platinum therapy, up to $100.0 million for first-line approval

Item EX-99.1 · Exhibit EX-99.1

  • RTOR NDA submission initiated for first-line EGFR exon20ins NSCLC, potentially accelerating FDA review
  • Completion expected by year-end 2026, with approval still uncertain
  • Phase 3 REZILIENT3 met its primary endpoint, showing statistically significant progression-free survival improvement
  • Existing monotherapy NDA remains under review, with PDUFA target date February 27, 2027
  • Approval milestones could generate $30 million for second-line and $100 million for first-line indications

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Cullinan Therapeutics, Inc. 8-K filings

Get the next CGEM 8-K as it lands

Follow CGEM for push alerts, or ask the research agent what this filing means.